lunes, 26 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

Sector Snapshot: AI Takes A Growing Share Of Sales And Marketing Startup Funding

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: Sector Snapshot: AI Takes A Growing Share Of Sales And Marketing Startup Funding Date: 2026-09-15 11:00 Source: https://news.crunchbase.com/sales-marketing/ai-growing-share-ecommerce-saas-crm-startup-funding/ <p>Businesses may be watching their software budgets more closely, but they…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Clay expects $240 million in ARR by the end of the fiscal year

    60% confidence

  • Clay is on track to hit $200 million in ARR this quarter

    60% confidence

  • Clay's revenue grew 4x in 2025

    60% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,994
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,994 hechos verificados con la fuente5,500 documentos fuente archivados
Consulta estos datos → isubstrate.com